An experienced antitrust lawyer, Alicia Batts has a well-established practice representing clients in mergers and acquisitions, as well as general investigations, before federal and state agencies. Her agency and counseling practice includes consumer protection matters before the FTC and state authorities. Her federal antitrust litigation practice spans the full range of antitrust and unfair competition-related litigation, including class actions and competitor suits.

    Earlier in her career, Alicia served as an Attorney Advisor to Federal Trade Commissioner Mozelle Thompson, for whom she reviewed antitrust actions before the FTC and made recommendations on enforcement and policy matters before the federal antitrust agency.

    Alicia’s experience, both as a government antitrust attorney and as a trusted legal and business advisor to high-profile multinational companies, brings invaluable insight on issues critical to clients. In particular, Alicia has considerable experience offering sophisticated services to clients in the pharmaceutical and chemicals industries.

    Alicia is active within the American Bar Association, serving as vice-chair of the Emerging Issues in Healthcare Law Conference Planning Committee, and having previously served as vice-chair of the Antitrust Section Business Torts & Civil RICO Committee, Antitrust Section Litigation Task Force and Clayton Act Committee. She is also a former member of the editorial board of the Antitrust Law Journal.

    Alicia was recognized by Black Enterprise among “America’s Top Black Lawyers”

    Award Mouse thought multimedia interface book medal screen monitor
    • Representing Grifols S.A. in its US$4.1 billion acquisition of Talecris Biotherapeutics Holdings Corp. and its US$1.7 billion agreement to acquire the transfusion unit of Novartis Vaccines & Diagnostics, Inc.
    • Representing an investor group in a US$6 billion acquisition, which was recognized as The American Lawyer’s 2014 Global M&A Deal of the Year.
    • Representing the Lonza Group in its US$1.4 billion tender for Arch Chemicals, Inc., resulting in the early termination of the HSR waiting period.
    • Representing hospital systems and associations before the federal antitrust agencies and courts.


    • Columbia Law School, J.D.
    • Harvard College, A.B.


    • District of Columbia, 1993
    • New York, 1991

    {{}} {{insights.source}} {{insights.type}}

    • Presenter, “Sherman’s (and Clayton’s) March: Emerging Issues in Antitrust Enforcement,” ABA 2016 Section of Litigation Annual Conference, Chicago, April 15, 2016.
    • Presenter, “Merger Clearance, HSR and Getting to Closing,” Bloomberg BNA live webcast series, September 22, 2015.
    • Presenter, “Improving Hospital Costs and Quality: How Does a Transaction Structure Matter, and What Does Antitrust Have to Say About It?” American Bar Association Health Law Section’s 16th Annual Conference on Emerging Issues in Healthcare Law, Lake Buena Vista, Florida, March 6, 2015.

    Award Mouse thought multimedia interface book medal screen monitor